{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/TEVA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# TEVA PHARMACEUTICAL INDUSTRIES LTD (NYSE: TEVA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is TEVA PHARMACEUTICAL INDUSTRIES LTD, listed on the NYSE under ticker TEVA. The ISIN is not on the record, and the LEI is not on the record. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Israel. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 157 filings in the twelve months to 2026-11-08, across 70 filing days. The median gap between filing days is 3 days, and the latest filing was 2 days before the record date. The latest filing is dated 2026-11-06 and is of type directors_dealings. The NYSE median is 6.0 days for cadence gap, 64.0 filings and 4.0 days latency across 3256 issuers. The 2834 Pharmaceutical Preparations sector median is 6.0 days for cadence gap, 63.0 filings and 4.0 days latency across 526 issuers. The issuer's 157 filings are above the NYSE median of 64.0 and above the sector median of 63.0. Its 3-day median gap is below both the NYSE and sector medians of 6.0 days.\n\n## Auditor\n\nThe auditor of record is Kesselman & Kesselman, and its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds a listing on 2026-09-14 and a delisting dated 2026-09-14. No name change is on the record. A domicile change and a segment move are not on the record. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 15 research houses: Argus Research Company, Barclays, Evercore ISI, Goldman Sachs, H.C Wainwright, Jefferies, JPMorgan, Leader Capital Markets, Leerink Partners, Morningstar, Oppenheimer & Co., Piper Sandler, Scotiabank, USA, TD Securities, and UBS (US).\n\n## Open research\n\nNo openly published research notes were found.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://data.sec.gov/submissions/CIK0000818686.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NYSE/TEVA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx (coverage)\n- https://mcp.us-cm-kg.ai/record/NYSE/TEVA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm",
    "state": "sourced",
    "value": "Kesselman & Kesselman"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm",
    "state": "sourced",
    "value": "1309"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/TEVA",
  "coverage": {
   "count": 15,
   "houses": [
    {
     "analyst": "Jasper Hellweg",
     "house": "Argus Research Company",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Glen Santangelo",
     "house": "Barclays",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Umer Raffat",
     "house": "Evercore ISI",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Matt Dellatorre",
     "house": "Goldman Sachs",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Douglas Tsao",
     "house": "H.C Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Dennis Ding",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Christopher T. Schott",
     "house": "JPMorgan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Sabina Levy",
     "house": "Leader Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Daniel Clark",
     "house": "Leerink Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Keonhee Kim",
     "house": "Morningstar",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Les Sulewski",
     "house": "Oppenheimer & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "David A. Amsellem",
     "house": "Piper Sandler",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Louise Chen",
     "house": "Scotiabank, USA",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Joe Thome",
     "house": "TD Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Ashwani Verma",
     "house": "UBS (US)",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx",
     "result": "read: 15 of 32 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "ad_hoc": 1,
    "agm_egm": 3,
    "corporate_news": 5,
    "director_change": 1,
    "directors_dealings": 86,
    "halt_suspension": 1,
    "prospectus": 2,
    "regulatory_filing": 49,
    "results": 9
   },
   "cadence_median_gap_days": 3,
   "filing_days": 70,
   "filings": 157,
   "latency_days": 2,
   "latest": [
    {
     "category": "4",
     "date": "2026-11-06",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000119312526451814/xslF345X06/ownership.xml",
     "title": "4 — 4",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-11-06",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000119312526451804/xslF345X06/ownership.xml",
     "title": "4 — 4",
     "type": "directors_dealings"
    },
    {
     "category": "144",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000197337926000362/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "144",
     "date": "2026-11-04",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000197337926000356/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "8-K",
     "date": "2026-11-03",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/f8k_110326.htm",
     "title": "8-K — FORM 8-K (items 2.02,9.01)",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-11-06",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/TEVA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "market": "US",
    "reason": "no LEI, so no GLEIF ISIN route; EDGAR carries no ISIN",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000818686.json",
    "state": "sourced",
    "value": "Israel"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-L3",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000818686.json",
    "state": "sourced",
    "value": "TEVA PHARMACEUTICAL INDUSTRIES LTD"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000818686.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000818686.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "TEVA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [
    {
     "date": "2026-09-14",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000087666126000744/xslF25X02/primary_doc.xml",
     "title": "25-NSE"
    }
   ],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2026-09-14",
     "source": "https://www.sec.gov/Archives/edgar/data/818686/000119312526390559/d534259d8a12ba.htm",
     "title": "8-A12B/A — 8-A12B/A"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:23d0c6b084b08a5e3601f18946470150254feaaae6e207d6e421b3d6c09610f5",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/TEVA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:23d0c6b084b08a5e3601f18946470150254feaaae6e207d6e421b3d6c09610f5",
 "path": "/us/NYSE/TEVA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is TEVA PHARMACEUTICAL INDUSTRIES LTD, listed on the NYSE under ticker TEVA. The ISIN is not on the record, and the LEI is not on the record. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Israel. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 157 filings in the twelve months to 2026-11-08, across 70 filing days. The median gap between filing days is 3 days, and the latest filing was 2 days before the record date. The latest filing is dated 2026-11-06 and is of type directors_dealings. The NYSE median is 6.0 days for cadence gap, 64.0 filings and 4.0 days latency across 3256 issuers. The 2834 Pharmaceutical Preparations sector median is 6.0 days for cadence gap, 63.0 filings and 4.0 days latency across 526 issuers. The issuer's 157 filings are above the NYSE median of 64.0 and above the sector median of 63.0. Its 3-day median gap is below both the NYSE and sector medians of 6.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Kesselman & Kesselman, and its location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds a listing on 2026-09-14 and a delisting dated 2026-09-14. No name change is on the record. A domicile change and a segment move are not on the record. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 15 research houses: Argus Research Company, Barclays, Evercore ISI, Goldman Sachs, H.C Wainwright, Jefferies, JPMorgan, Leader Capital Markets, Leerink Partners, Morningstar, Oppenheimer & Co., Piper Sandler, Scotiabank, USA, TD Securities, and UBS (US).",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0000818686.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/TEVA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/TEVA"
  }
 ],
 "title": "TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}